These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17638514)

  • 1. Controlled ovarian hyperstimulation pharmacogenetics: a simplified model to genetically dissect estrogen-related diseases.
    Morón FJ; Galán JJ; Ruiz A
    Pharmacogenomics; 2007 Jul; 8(7):775-85. PubMed ID: 17638514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of controlled ovarian hyperstimulation.
    de Castro F; Morón FJ; Montoro L; Real LM; Ruiz A
    Pharmacogenomics; 2005 Sep; 6(6):629-37. PubMed ID: 16143002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?
    Altmäe S; Hovatta O; Stavreus-Evers A; Salumets A
    Hum Reprod Update; 2011; 17(6):813-28. PubMed ID: 21862569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers.
    Morón FJ; Ruiz A
    Pharmacogenomics; 2010 Nov; 11(11):1613-8. PubMed ID: 21121812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS).
    Morón FJ; de Castro F; Royo JL; Montoro L; Mira E; Sáez ME; Real LM; González A; Mañes S; Ruiz A
    Pharmacogenet Genomics; 2006 Jul; 16(7):485-95. PubMed ID: 16788381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathology of the FSH receptor: new insights into FSH physiology.
    Meduri G; Bachelot A; Cocca MP; Vasseur C; Rodien P; Kuttenn F; Touraine P; Misrahi M
    Mol Cell Endocrinol; 2008 Jan; 282(1-2):130-42. PubMed ID: 18248882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in ovarian stimulation--current concepts.
    Loutradis D; Vlismas A; Drakakis P; Antsaklis A
    Ann N Y Acad Sci; 2008 Apr; 1127():10-9. PubMed ID: 18443324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
    Casper RF; Mitwally MF
    Clin Obstet Gynecol; 2011 Dec; 54(4):685-95. PubMed ID: 22031258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates--a randomized, double-blinded, placebo-controlled trial.
    Cantineau AE; Cohlen BJ; Klip H; Heineman MJ;
    Hum Reprod; 2011 May; 26(5):1104-11. PubMed ID: 21339196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH antagonists in controlled ovarian hyperstimulation protocols in assisted reproductive technique programmes--current concepts.
    Jindal UN
    J Indian Med Assoc; 2006 Aug; 104(8):450, 452, 454 passim. PubMed ID: 17240802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.
    Hanevik HI; Hilmarsen HT; Skjelbred CF; Tanbo T; Kahn JA
    Gynecol Endocrinol; 2012 Nov; 28(11):845-9. PubMed ID: 22587628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clomiphene, ovarian hyperstimulation syndrome and pregnancy].
    Samsonia MD; Lesnovskaia EE; Kandelaki MA
    Georgian Med News; 2009 Jan; (166):26-9. PubMed ID: 19202213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-Müllerian hormone--its role in management of involuntary infertility].
    Kalra GS
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):409-11. PubMed ID: 19247400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future developments to minimize ART risks.
    Marzal A; Holzer H; Tulandi T
    Semin Reprod Med; 2012 Apr; 30(2):152-60. PubMed ID: 22549715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulsatile gonadotropin releasing hormone treatment following previous ovarian hyperstimulation].
    Koloszár S; Bártfai G
    Orv Hetil; 1993 Jul; 134(28):1521-3. PubMed ID: 8341530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we eliminate severe ovarian hyperstimulation syndrome?
    Orvieto R
    Hum Reprod; 2005 Feb; 20(2):320-2. PubMed ID: 15567876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro oocyte maturation for safer treatment of infertility. The risk of ovarian overstimulation syndrome is minimized].
    Hreinsson J; Fridström M
    Lakartidningen; 2004 Nov; 101(46):3665-8, 3671. PubMed ID: 15586490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pituitary down-regulation and ovulation stimulation with gradually increased gonadotropin in controlled ovarian hyperstimulation].
    Zhu L; Song YL; Cui YG; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):361-3. PubMed ID: 17425993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic complexity of FSH receptor function.
    Gromoll J; Simoni M
    Trends Endocrinol Metab; 2005 Oct; 16(8):368-73. PubMed ID: 16126408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.